β-blockers for heart failure:: why, which, when, and where

被引:19
作者
Cleland, JGF [1 ]
机构
[1] Univ Hull, Dept Cardiol, Kingston Upon Hull HU16 5JQ, Yorks, England
关键词
D O I
10.1016/S0025-7125(02)00173-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Some patience, perseverance, and education are required in order to allow patients to reap the full benefits of beta-blocker therapy for heart failure. Initiation of treatment early in the course of the disease maximizes the effectiveness and acceptance of therapy. Trials are under way to determine whether the benefits of beta-blockers extend to patients over 80 years of age and to those with preserved LV systolic function. It is likely that important differences exist between beta-blockers in terms of their clinical benefit, though whether differences exist between the agents that have been reported to be effective so far awaits the outcome of a large clinical trial. It is unclear whether the target doses of beta-blockers currently recommended are optimal.
引用
收藏
页码:339 / +
页数:34
相关论文
共 110 条
[81]   Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure [J].
O'Keefe, JH ;
Magalski, A ;
Stevens, TL ;
Bresnahan, DR ;
Alaswad, K ;
Krueger, SK ;
Bateman, TM .
JOURNAL OF NUCLEAR CARDIOLOGY, 2000, 7 (01) :3-7
[82]   CARVEDILOL, A CARDIOVASCULAR DRUG, PREVENTS VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION, MIGRATION, AND NEOINTIMAL FORMATION FOLLOWING VASCULAR INJURY [J].
OHLSTEIN, EH ;
DOUGLAS, SA ;
SUNG, CP ;
YUE, TL ;
LOUDEN, C ;
ARLETH, A ;
POSTE, G ;
RUFFOLO, RR ;
FEUERSTEIN, GZ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :6189-6193
[83]  
Pacher R, 1997, WIEN KLIN WOCHENSCHR, V109, P232
[84]   Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure - The PRECISE trial [J].
Packer, M ;
Colucci, WS ;
SacknerBernstein, JD ;
Liang, CS ;
Goldscher, DA ;
Freeman, I ;
Kukin, ML ;
Kinhal, V ;
Udelson, JE ;
Klapholz, M ;
Gottlieb, SS ;
Pearle, D ;
Cody, RJ ;
Gregory, JJ ;
Kantrowitz, NE ;
LeJemtel, TH ;
Young, ST ;
Lukas, MA ;
Shusterman, NH .
CIRCULATION, 1996, 94 (11) :2793-2799
[85]   Effect of carvedilol on survival in severe chronic heart failure. [J].
Packer, M ;
Coats, AJS ;
Fowler, MB ;
Katus, HA ;
Krum, H ;
Mohacsi, P ;
Rouleau, JL ;
Tendera, M ;
Castaigne, A ;
Roecker, EB ;
Schultz, MK ;
DeMets, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (22) :1651-1658
[86]   The effect of carvedilol on morbidity and mortality in patients with chronic heart failure [J].
Packer, M ;
Bristow, MR ;
Cohn, JN ;
Colucci, WS ;
Fowler, MB ;
Gilbert, EM ;
Shusterman, NH .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (21) :1349-1355
[87]   Comparative effects of carvedilol and metoprolol on left ventricular election fraction in heart failure: Results of a meta-analysis [J].
Packer, M ;
Antonopoulos, GV ;
Berlin, JA ;
Chittams, J ;
Konstam, MA ;
Udelson, JE .
AMERICAN HEART JOURNAL, 2001, 141 (06) :899-907
[88]  
PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801
[89]   Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II [J].
Pitt, B ;
Poole-Wilson, PA ;
Segal, R ;
Martinez, FA ;
Dickstein, K ;
Camm, AJ ;
Konstam, MA ;
Riegger, G ;
Klinger, GH ;
Neaton, J ;
Sharma, D ;
Thiyagarajan, B .
LANCET, 2000, 355 (9215) :1582-1587
[90]   The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].
Pitt, B ;
Zannad, F ;
Remme, WJ ;
Cody, R ;
Castaigne, A ;
Perez, A ;
Palensky, J ;
Wittes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717